Attacking Devastating Diseases Attacking Devastating Diseases With Breakthrough Science With Breakthrough Science Neuroscience Neuroscience Martin Mackay, Ph.D. Martin Mackay, Ph.D. Senior Vice President Senior Vice President Worldwide Research and Technology Worldwide Research and Technology Valid as of November 30, 2006
14
Embed
Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Attacking Devastating Diseases Attacking Devastating Diseases With Breakthrough Science With Breakthrough Science
NeuroscienceNeuroscienceMartin Mackay, Ph.D.Martin Mackay, Ph.D.Senior Vice PresidentSenior Vice President
Worldwide Research and TechnologyWorldwide Research and Technology
Valid as of November 30, 2006
Neuroscience VisionNeuroscience Vision
We will Change Society We will Change Society by Lifting the Burden ofby Lifting the Burden of
Neuropsychiatric DiseaseNeuropsychiatric Disease
Valid as of November 30, 2006
Progress in Our LifetimesProgress in Our Lifetimes
Strategy in BriefStrategy in Brief
AlzheimerAlzheimer’’s Disease s Disease –– Fully Exploit Fully Exploit Scientific BreakthroughsScientific BreakthroughsCognition and ADHD Cognition and ADHD –– Increased Effort Builds Increased Effort Builds Upon Internal DiscoveriesUpon Internal DiscoveriesBipolar Disorder and Schizophrenia Bipolar Disorder and Schizophrenia –– Advance Advance Several Programs Into The ClinicSeveral Programs Into The ClinicDepression and Anxiety Depression and Anxiety –– Leverage New Science Leverage New Science to Discover Novel Targetsto Discover Novel TargetsSleep Quality Sleep Quality –– Mine the Mine the αα22δ δ AdvancesAdvances
Valid as of November 30, 2006
Phase 1Phase 1
PreclinicalPreclinical
Phase 3Phase 3
Phase 2Phase 2
A Substantial And Broad ProgramA Substantial And Broad Program
Lyrica for FibromyalgiaLyrica for Fibromyalgia
Alpha 2 Delta for GAD; Alpha 2 Delta Alpha 2 Delta for GAD; Alpha 2 Delta for Insomnia; RAGE for ADDMfor Insomnia; RAGE for ADDM
mAb for Pain; mAb for Pain; PGE2/EP4 for OA; PGE2/EP4 for OA; NRI for NeP/FibromyalgiaNRI for NeP/Fibromyalgia
SSRI/5HT1b for DepressionSSRI/5HT1b for Depression
27 Candidates for Schizophrenia, 27 Candidates for Schizophrenia, ADDM, ADHD, Anxiety, ADDM, ADHD, Anxiety, Depression and PainDepression and Pain
2 Candidates for ADDM (A2 Candidates for ADDM (Aββ & RAGE & RAGE mAbmAb))7 Candidates for Schizophrenia, 7 Candidates for Schizophrenia,
Depression & PainDepression & Pain
Valid as of November 30, 2006
Key ProgramsKey Programs
Lyrica for Fibromyalgia* Lyrica for Fibromyalgia* S,SS,S--Reboxetine for Neuropathic Pain*Reboxetine for Neuropathic Pain*αα22δδ Platform*Platform*AlzheimerAlzheimer’’s Diseases Disease
Chronic, NonChronic, Non--Malignant Malignant Pain Where the Central Pain Where the Central Nervous System is Nervous System is MalfunctioningMalfunctioning
S,SS,S--Reboxetine is a Highly Reboxetine is a Highly Selective Norepinephrine Selective Norepinephrine Reuptake Inhibitor (NRI)Reuptake Inhibitor (NRI)
ControlledControlled--Release Release Formulation for Formulation for OnceOnce--Daily AdministrationDaily Administration
Valid as of November 30, 2006
Pain Relief in Treatment FailuresPain Relief in Treatment Failures
Placebo
S,S-Reboxetine
Placebo
S,S-Reboxetine
44
55
66
77
Wee
kly
Aver
age
Pain
Sco
reW
eekl
y Av
erag
e Pa
in S
core
11 5544332200
Time (Weeks)Time (Weeks)
Valid as of November 30, 2006
A Thriving A Thriving αα22δδ PortfolioPortfolio
α2δαα22δδ
AnxietyAnxietyAnxiety
SleepSleepSleep
Hot FlashesHot FlashesHot Flashes
PF-293,765
PF-2,393,296
Lyrica
PF-293,765
PF-2,393,296
Lyrica
PD-332,334
Lyrica
PD-332,334
Lyrica
PD-200,390 PD-200,390
PD-299,685PD-299,685
PainPain
NeuroscienceNeuroscience
Women’s HealthWomen’s Health
Neuropathic Pain
Neuropathic Neuropathic PainPain
Valid as of November 30, 2006
PDPD--332,334 332,334 Impressive Results in AnxietyImpressive Results in Anxiety
13%13%
29%29%26%26%
31%31%
48%48%
38%38%
0%0%
10%10%
20%20%
30%30%
40%40%
50%50%
Res
pond
er R
ates
(%)
Res
pond
er R
ates
(%)
Week 1Week 1 Week 4Week 4
% of Patients Greater Than or % of Patients Greater Than or Equal to 50% Reduction HAMEqual to 50% Reduction HAM--AA
PlaceboPlacebo
PDPD--332,334 250mg BID332,334 250mg BID
XanaxXR 1mg BIDXanaxXR 1mg BID
Valid as of November 30, 2006
PDPD--200,390 200,390 A Breakthrough for Sleep QualityA Breakthrough for Sleep Quality
Insomnia Impacts 50% Insomnia Impacts 50% of General Populationof General Population
10% of General 10% of General Population Suffer from Population Suffer from Poor Sleep QualityPoor Sleep Quality
Program Covers Program Covers Insomnia and Insomnia and Sleep QualitySleep Quality
Valid as of November 30, 2006
PDPD--200,390200,390Total Sleep TimeTotal Sleep Time